Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Genetic risk stratification in adults with AML receiving venetoclax-based intensive therapy: A real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

SPShanshan PeiCell Technology (China)WZWeiyan ZhengCell Technology (China)YZYi ZhaoJiangsu Province Hospital

Discussion

Loading...

Member takes

Overview

Real-world study demonstrates improved prognostic model for AML patients receiving venetoclax, suggesting better treatment personalization.

Key Points

  • This research aims to refine risk stratification for adults with AML undergoing venetoclax-based therapy.
  • Conducted a real-world study involving newly diagnosed AML patients receiving venetoclax and intensive chemotherapy.
  • Developed a prognostic model (ICV-CHN) based on genetic and cytogenetic features.
  • Utilized survival analysis techniques including Cox proportional hazards models and random survival forest algorithm.
  • Identified significant genetic markers associated with overall survival (OS) in AML patients.
  • Developed four risk groups based on genetic profiles, improving upon current ELN classifications.
  • ICV-CHN model demonstrated a 2-year OS rate of 91.4% for low-risk patients, outperforming ELN-based classifications.

Cite This Study

Pei et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da60https://doi.org/10.1182/blood-2025-3404
View Full Paper
Ask AI
Bookmark
Share